Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dietary triglycerides and other lipid substrates in the intestinal lumen are the primary dietary sources of energy and essential fatty acids for the human body. These lipids must undergo a complex process of emulsification by bile salts and enzymatic hydrolysis, primarily by pancreatic lipase, to be converted into absorbable units like free fatty acids and 2-monoacylglycerols (StatPearls, 2023). While these molecules are substrates rather than biological targets such as receptors or enzymes, they are the functional focus of therapeutic strategies for managing metabolic conditions. For instance, the weight-loss medication orlistat functions by covalently bonding to the active site of lipases, preventing them from breaking down these triglycerides and thus inhibiting their absorption (FDA, 2015). Proper management of these substrates is vital, as excessive lipid uptake is a driver of obesity and cardiovascular disease, whereas insufficient absorption can lead to steatorrhea and nutritional deficiencies (NIH, 2022).
Inhibition of lipase-mediated hydrolysis and intestinal absorption
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dietary triglycerides and other lipid substrates in the intestinal lumen (TG).